Neoplasia · 2008 · 52 citations · 38 references
PharmacyOncologyPharmaceuticsDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryCancer NanomedicineCell-nanoparticle InteractionsNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsNanoparticle FormulationsCancer NanotherapyMrna Cellular UptakeNanoparticle Cellular UptakeNanoparticle ConjugationNanoparticlesPolo-like Kinase InhibitionTargeted DeliveryTumor-targeted Drug Delivery
Human serum albumin (HSA) nanoparticles represent a promising tool for targeted drug delivery to tumor cells. The coupling of the antibody trastuzumab to nanoparticles uses the capability of human epidermal growth factor receptor 2 (HER2)-positive cells to incorporate agents linked to HER2. In our present study, we developed targeted nanoparticles loaded with antisense oligonucleotides (ASOs) against polo-like kinase 1 (Plk1). We evaluated the receptor-mediated uptake into HER2-positive and -negative breast cancer and murine cell lines. We performed quantitative real-time PCR and Western blot analyses to monitor the impact on Plk1 expression in HER2-positive breast cancer cells. Antibody-conjugated nanoparticles showed a specific targeting to HER2-overexpressing cells with cellular uptake by receptor-mediated endocytosis and a release into HER2-positive BT-474 cells. We observed a significant reduction of Plk1 mRNA and protein expression and increased activation of Caspase 3/7. Thus, this is the first report about ASO-loaded HSA nanoparticles, where an impact on gene expression could be observed. The data provide the basis for the further development of carrier systems for Plk1-specific ASOs to reduce off-target effects evoked by systemically administered ASOs and to achieve a better penetration into primary and metastatic target cells. Treatment of tumors using trastuzumab-conjugated ASO-loaded HSA nanoparticles could be a promising approach to reach this goal.
38
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text
Dmitri B. Kirpotin, Daryl C. Drummond, Yi Shao et al. · Cancer Research · 2006 · 1.1K citations · Full text
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Martin Steegmaier, Matthias Hoffmann, Anke Baum et al. · Current Biology · 2007 · 849 citations · Full text
Medicine, Oncology, Pharmacology +14